AI Strategy Lead in Portfolio & Innovation at Pfizer
Andrew is an AI Strategy Lead in Portfolio & Innovation at Pfizer. His work is focused on identifying, building, testing, implementing and scaling AI-enabled tools that support clinical study simulation, design, and optimization. His objective for this technology is to use it as a force multiplier and decision support for drug development professionals, allowing them to spend more time on the most important elements of their work, helping bring better medicines to patients, faster.
Andrew has held leadership roles in cross-functional drug development for more than two decades. During that time, he has worked end-to-end, from discovery to post-marketing, on large and small molecules, vaccines, diagnostics, real world data and vector control. He has had the privilege of working with extraordinary teams at Amgen, The Bill & Melinda Gates Foundation, Seagen and Pfizer. Throughout, Andrew has kept one foot firmly planted in the realm of digital innovation, seeking to weave emergent technology into existing methods.